Indivior Pharmaceuticals, Inc. Most Important Performance Measures
The measures each proxy statement lists as most important for linking pay to performance (Item 402(v) tabular list), as tagged, newest proxy first.
- 2023-05-01: Measure Gross Product Sales.
- 2023-05-01: Measure Operating Income.
- 2024-04-29: Measure Gross Product Sales.
- 2024-04-29: Measure Operating Income.
| Proxy filed | Measure |
|---|---|
| 2023-05-01 | Gross Product Sales |
| 2023-05-01 | Operating Income |
| 2024-04-29 | Gross Product Sales |
| 2024-04-29 | Operating Income |
| 2025-04-30 | Gross Product Sales |
| 2025-04-30 | Operating Earnings |
| 2026-04-30 | Gross Product Sales |
| 2026-04-30 | Operating Earnings |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |